| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:MAP3K8_LYZL2 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: MAP3K8_LYZL2 | KinaseFusionDB ID: KFG3450 | FusionGDB2.0 ID: KFG3450 | Hgene | Tgene | Gene symbol | MAP3K8 | LYZL2 | Gene ID | 1326 | 119180 | |
| Gene name | mitogen-activated protein kinase kinase kinase 8 | lysozyme like 2 | ||||||||||
| Synonyms | AURA2|COT|EST|ESTF|MEKK8|TPL2|Tpl-2|c-COT | LYZD2 | ||||||||||
| Cytomap | 10p11.23 | 10p11.23 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | mitogen-activated protein kinase kinase kinase 8Ewing sarcoma transformantaugmented in rheumatoid arthritis 2cot (cancer Osaka thyroid) oncogeneproto-oncogene c-Cotproto-oncogene serine/threoine protein kinasetumor progression locus 2 | lysozyme-like protein 2lysozyme D2lysozyme-2 | ||||||||||
| Modification date | 20240403 | 20240305 | ||||||||||
| UniProtAcc | P41279 | Q7Z4W2 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000263056, ENST00000375321, ENST00000542547, ENST00000375322, | ENST00000375318, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: MAP3K8 [Title/Abstract] AND LYZL2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MAP3K8(30748430)-LYZL2(30900953), # samples:3 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Kinase Fusion gene breakpoints across MAP3K8 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across LYZL2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-FS-A1Z4-06A | MAP3K8 | chr10 | 30748430 | LYZL2 | chr10 | 30900953 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:30748430/:30900953) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| MAP3K8 | LYZL2 |
| FUNCTION: Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the pro-inflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. {ECO:0000269|PubMed:11342626, ECO:0000269|PubMed:12667451, ECO:0000269|PubMed:15169888, ECO:0000269|PubMed:16371247, ECO:0000269|PubMed:1833717, ECO:0000269|PubMed:19001140, ECO:0000269|PubMed:19808894}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of MAP3K8_LYZL2 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAP3K8 | P41279 | human | RDX | P35241 | T564 | AGRDKyKtLRQIRQG | ERM_C |
| MAP3K8 | P41279 | human | IRF3 | Q14653 | T180 | sPsLDNPtPFPNLGP | |
| MAP3K8 | P41279 | human | EZR | P15311 | T567 | QGRDkyKtLRQIRQG | ERM_C |
| MAP3K8 | P41279 | human | ABL1 | P00519 | T735 | DTEWRSVtLPRDLQS | |
| MAP3K8 | P41279 | human | MAP2K1 | Q02750 | S222 | LIDsMANsFVGtRSY | Pkinase |
| MAP3K8 | P41279 | human | RPS6KA1 | Q15418 | S380 | HQLFRGFsFVAtGLM | Pkinase_C |
| MAP3K8 | P41279 | human | CDK1 | P06493 | T161 | GIPIRVytHEVVTLW | Pkinase |
| MAP3K8 | P41279 | human | MAP2K1 | Q02750 | S218 | VsGQLIDsMANsFVG | Pkinase |
| MAP3K8 | P41279 | human | PLK1 | P53350 | S137 | LELCRRRsLLELHkR | Pkinase |
| MAP3K8 | P41279 | human | IRF3 | Q14653 | S175 | PQPLRsPsLDNPtPF | |
| MAP3K8 | P41279 | human | CHEK1 | O14757 | S345 | LVQGIsFsQPtCPDH | |
| MAP3K8 | P41279 | human | MAP2K2 | P36507 | S222 | VsGQLIDsMANsFVG | Pkinase |
| MAP3K8 | P41279 | human | NPM1 | P06748 | T199 | VkKsIrDtPAkNAQK | |
| MAP3K8 | P41279 | human | IRF3 | Q14653 | S123 | DFSQPDTsPDTNGGG | |
| MAP3K8 | P41279 | human | MAP2K3 | P46734 | S218 | IsGyLVDsVAKtMDA | Pkinase |
| MAP3K8 | P41279 | human | CREB1 | P16220 | S119 | EILsRRPsyRkILND | pKID |
| MAP3K8 | P41279 | human | EIF4G1 | Q04637 | S1147 | VVQRssLsRERGEKA | |
| MAP3K8 | P41279 | human | MAP2K6 | P52564 | S207 | IsGyLVDsVAKtIDA | Pkinase |
| MAP3K8 | P41279 | human | EIF4EBP1 | Q13541 | T70 | rNsPVtktPPRDLPt | eIF_4EBP |
| MAP3K8 | P41279 | human | PLK1 | P53350 | T210 | YDGERKktLCGtPNy | Pkinase |
| MAP3K8 | P41279 | human | MSN | P26038 | T558 | LGRDKyKtLRQIRQG | ERM_C |
| MAP3K8 | P41279 | human | IRF3 | Q14653 | S188 | PFPNLGPsENPLkRL | |
| MAP3K8 | P41279 | human | MAP2K2 | P36507 | S226 | LIDsMANsFVGtRSY | Pkinase |
| MAP3K8 | P41279 | human | H2BC3 | P33778 | S32 | DGKkRKRsRkEsysI | Histone |
| MAP3K8 | P41279 | human | IRF3 | Q14653 | S173 | PCPQPLRsPsLDNPt |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAP3K8 | ID | Description | 0.00e+00 |
| MAP3K8 | GO:2000641 | regulation of early endosome to late endosome transport | 5.77e-09 |
| MAP3K8 | GO:1903649 | regulation of cytoplasmic transport | 4.96e-08 |
| MAP3K8 | GO:0045022 | early endosome to late endosome transport | 1.55e-07 |
| MAP3K8 | GO:0048308 | organelle inheritance | 1.55e-07 |
| MAP3K8 | GO:0048313 | Golgi inheritance | 1.55e-07 |
| MAP3K8 | GO:0098927 | vesicle-mediated transport between endosomal compartments | 1.55e-07 |
| MAP3K8 | GO:0045787 | positive regulation of cell cycle | 2.28e-06 |
| MAP3K8 | GO:0042770 | signal transduction in response to DNA damage | 2.28e-06 |
| MAP3K8 | GO:0090398 | cellular senescence | 6.40e-06 |
| MAP3K8 | GO:0045931 | positive regulation of mitotic cell cycle | 1.23e-05 |
| MAP3K8 | GO:1903829 | positive regulation of protein localization | 1.43e-05 |
| MAP3K8 | GO:1902946 | protein localization to early endosome | 1.43e-05 |
| MAP3K8 | GO:1905668 | positive regulation of protein localization to endosome | 1.43e-05 |
| MAP3K8 | GO:1905666 | regulation of protein localization to endosome | 1.72e-05 |
| MAP3K8 | GO:1903651 | positive regulation of cytoplasmic transport | 2.55e-05 |
| MAP3K8 | GO:0032386 | regulation of intracellular transport | 3.43e-05 |
| MAP3K8 | GO:0016482 | cytosolic transport | 4.18e-05 |
| MAP3K8 | GO:0008361 | regulation of cell size | 4.52e-05 |
| MAP3K8 | GO:0032535 | regulation of cellular component size | 5.08e-05 |
| MAP3K8 | GO:0043555 | regulation of translation in response to stress | 5.58e-05 |
| MAP3K8 | GO:1902115 | regulation of organelle assembly | 8.25e-05 |
| MAP3K8 | GO:0051403 | stress-activated MAPK cascade | 1.03e-04 |
| MAP3K8 | GO:0036010 | protein localization to endosome | 1.04e-04 |
| MAP3K8 | GO:0018107 | peptidyl-threonine phosphorylation | 1.04e-04 |
| MAP3K8 | GO:0031098 | stress-activated protein kinase signaling cascade | 1.06e-04 |
| MAP3K8 | GO:0048732 | gland development | 1.06e-04 |
| MAP3K8 | GO:1901987 | regulation of cell cycle phase transition | 1.20e-04 |
| MAP3K8 | GO:0018210 | peptidyl-threonine modification | 1.29e-04 |
| MAP3K8 | GO:0045927 | positive regulation of growth | 1.29e-04 |
| MAP3K8 | GO:0044772 | mitotic cell cycle phase transition | 1.29e-04 |
| MAP3K8 | GO:1902749 | regulation of cell cycle G2/M phase transition | 1.46e-04 |
| MAP3K8 | GO:1901989 | positive regulation of cell cycle phase transition | 1.56e-04 |
| MAP3K8 | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 1.96e-04 |
| MAP3K8 | GO:0018105 | peptidyl-serine phosphorylation | 2.24e-04 |
| MAP3K8 | GO:0007098 | centrosome cycle | 2.57e-04 |
| MAP3K8 | GO:0018209 | peptidyl-serine modification | 2.61e-04 |
| MAP3K8 | GO:0060428 | lung epithelium development | 2.96e-04 |
| MAP3K8 | GO:0031023 | microtubule organizing center organization | 3.53e-04 |
| MAP3K8 | GO:0044839 | cell cycle G2/M phase transition | 3.53e-04 |
| MAP3K8 | GO:0070371 | ERK1 and ERK2 cascade | 3.53e-04 |
| MAP3K8 | GO:0007030 | Golgi organization | 3.53e-04 |
| MAP3K8 | GO:0048538 | thymus development | 3.53e-04 |
| MAP3K8 | GO:0061028 | establishment of endothelial barrier | 3.53e-04 |
| MAP3K8 | GO:1901990 | regulation of mitotic cell cycle phase transition | 4.24e-04 |
| MAP3K8 | GO:0044818 | mitotic G2/M transition checkpoint | 4.28e-04 |
| MAP3K8 | GO:0038066 | p38MAPK cascade | 5.22e-04 |
| MAP3K8 | GO:0030324 | lung development | 6.48e-04 |
| MAP3K8 | GO:0030323 | respiratory tube development | 6.89e-04 |
| MAP3K8 | GO:0001885 | endothelial cell development | 6.95e-04 |
Top |
Related Drugs to MAP3K8_LYZL2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning MAP3K8-LYZL2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to MAP3K8_LYZL2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |